TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03460145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender Oil on Nasal Strip (Lx)
Description: Usage of Aromatherapy for Preoperative Anxiety

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strip without Lavender Oil (Px)
Description: Strip without Lavender Oil (Px)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 1 % Injectable Suspension
Description: Propofol 1% (10mg/mL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol 1 % Injectable Suspension
Description: Propofol 1% (10mg/mL)
Study: NCT03639220

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation Therapy (PBMT)
Description: Phototherapy device - Multi Radiance Medical™ (Solon, OH, EUA)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation Therapy (PBMT)
Description: Phototherapy device - Multi Radiance Medical™ (Solon, OH, EUA)
Study: NCT00375791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Description: 100 - 150 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Description: 100 - 150 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 20 mg twice weekly
Study: NCT03666325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab at 200 mg every 3 weeks for 9 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: In case of first progression or no response cetuximab will be added at a weekly dose of 250 mg.
Study: NCT01122589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing/CBT
Description: 6 sessions of in jail MI/CBT counseling will be administered.
Study: NCT01561378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspart insulin
Description: 40 IU of aspart insulin (200 microliters per nostril) will be administered intranasally using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
Study: NCT01117441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: see detailed protocol description
Study: NCT01122589

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONcise Tapes Reviewing Obstacles to healthy Living (CONTROL)
Description: a series of six weekly 30-45 minutes general wellness videos
Study: NCT05066568

Intervention type: DEVICE
Group type: OTHER
Intervention: Active Tracranial Direct Current Stimulation
Description: Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 2mA Stimulation time: 20 min The current ramps up during 30 seconds reaching 2mA, staying this way until the last 30 seconds of stimulation, in wich the current slowly decreases to zero.

Intervention type: DEVICE
Group type: OTHER
Intervention: Active Tracranial Direct Current Stimulation
Description: Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 2mA Stimulation time: 20 min The current ramps up during 30 seconds reaching 2mA, staying this way until the last 30 seconds of stimulation, in wich the current slowly decreases to zero.
Study: NCT01561378

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 200 microliters of normal saline will be administered per nostril using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal mucosal atomizer device
Description: Insulin and placebo will be drawn into identical syringes. Nurses will administer the insulin or placebo by connecting the mucosal atomizer device (MAD) to the syringe, placing the MAD tip in the nostril and compressing the syringe plunger to spray atomized solution into the nasal cavity.
Study: NCT02238132

Intervention type: DRUG
Intervention: ATROVENT® inhalets
Study: NCT03785691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning).~On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days.
Study: NCT02476188

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sample of Blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sample of Blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sample of Blood
Study: NCT03255434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Simplified FOLFOX 4 regimen: Association of Oxaliplatin (85 mg/m² ) + simplified LV5FU2 Length of a cycle : 2 days Interval between 2 cycles : 2 weeks (D1=D15) Expected number of cycles: 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin LBM
Description: Simplified FOLFOX 4 regimen: Association of Oxaliplatin (LBM) + simplified LV5FU2
Study: NCT03840382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-PrEP Intervention
Description: Telemedicine conferences with PrEP-specialists
Study: NCT03332251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posture Correction Girdle
Description: Participants will be invited to undergo a fitting session of posture correction girdle. After the fitting, participants will join a 6-month wear trial of the posture correction girdle. Participants are required to wear the girdle for 8 hours a day and the compliance will be recorded by a logbook daily. Participants will be invited to undergo assessments before the wear trial, after the trial of 3 months, and after the trial of 6 months. The measure outcomes of the assessment include 1) ultrasound scanning image, 2) 3D body scan, 3) electromyography signal, 4) garment pressure, and 5) questionnaire.
Study: NCT00932724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY-503
Description: Ampoules with 1 ml 350 ng CY-503 solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ampoules with 1 ml placebo solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
Study: NCT00934180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 1 x 8 mg Orally Disintegrating Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran®
Description: 1 x 8 mg ODT
Study: NCT01561378

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal mucosal atomizer device
Description: Insulin and placebo will be drawn into identical syringes. Nurses will administer the insulin or placebo by connecting the mucosal atomizer device (MAD) to the syringe, placing the MAD tip in the nostril and compressing the syringe plunger to spray atomized solution into the nasal cavity.
Study: NCT01212107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF Receptor
Description: LY2874455 administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF Receptor
Description: LY2874455 administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF Receptor
Description: LY2874455 administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF Receptor
Description: LY2874455 administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF Receptor
Description: LY2874455 administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF Receptor
Description: LY2874455 administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF Receptor
Description: LY2874455 administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF Receptor
Description: LY2874455 administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF Receptor
Description: LY2874455 administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF Receptor
Description: LY2874455 administered orally.
Study: NCT00835172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg Tablets
Description: 1 x 4 mg, single-dose non-fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMARYL® 4 mg Tablets
Description: 1 x 4 mg, single-dose non-fasting
Study: NCT04501718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Combined With Temozolomide and Etoposide Capsules
Description: Apatinib mesylate tablets: Oral, 250mg, qd. Take the medicine with warm water half an hour after a meal (the daily medicine should be taken at the same time as possible).~28 days is a cycle, and the medication is administered until the disease progresses (PD), intolerable toxicity occurs or the patient withdraws informed consent. The longest period does not exceed 12 cycles. The treatment after 12 cycles is determined by the investigator.
Study: NCT00834197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 mg (Orally Disintegrating) Tablets
Description: 1 x 15 mg, single-dose non-fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REMERON SolTab® 15 mg Orally Disintegrating Tablets
Description: 1 x 15 mg, single-dose non-fasting
Study: NCT05919563

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Observational study; annual MRI for first 5 years only to monitor changes in the injection site
Study: NCT01905397

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negative pressure wound therapy
Description: The Prevena Incision Management System covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump may be used with the Prevena dressings as well in some situations to achieve negative pressure.
Study: NCT02549911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIPEC,Chemotherapy AND surgery
Description: 1. HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~2. chemotherapy(PS for 3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~3. surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )~4. after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles
Study: NCT02718794

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simulation training
Description: spend 3 hours for each of 10 nurse anesthetist students with 4 scenarios

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simulation training
Description: spend 3 hours for each of 10 nurse anesthetist students with 4 scenarios

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Problem-based learning
Description: spend 3 hours for PBL steps with each of 10 nurse anesthetist students

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Problem-based learning
Description: spend 3 hours for PBL steps with each of 10 nurse anesthetist students
Study: NCT03206034

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stylistic Memory Enhancement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stylistic Memory Enhancement
Study: NCT01975272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous fumarate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for ferrous fumarate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ferrous fumarate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for ferinject

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ferinject
Study: NCT03209024

Intervention type: OTHER
Group type: OTHER
Intervention: Handwritten logbook recording of home blood pressure readings
Description: Participants use a handwritten logbook to record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone assisted wireless recording of home blood pressure readings
Description: Participants use a smartphone app and Bluetooth® technology to wirelessly record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
Study: NCT01166815

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc sulphate
Description: Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
Study: NCT01812629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Infant formula to be fed ad libitum
Study: NCT01543867

Intervention type: DRUG
Intervention: somatropin
Description: Prescribed at the discretion of the treating physician according to product labelling
Study: NCT02498249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: Will be performed irradiation with low-intensity laser in upper trapezius muscle

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo low level laser therapy
Description: Will be not performed irradiation with low-intensity laser in upper trapezius muscle
Study: NCT04593147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BBN
Description: BBN to be fed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brand
Description: Brand to be fed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks
Study: NCT03610919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Sprays
Description: Intranasal administration of 24 international units per dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Sprays
Description: Intranasal administration of 24 international units per dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Sprays
Description: Intranasal administration of 24 international units per dose.
Study: NCT00687882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shortened duration (6 weeks) of anticoagulant therapy
Description: Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional duration (3 months) of anticoagulant therapy
Description: Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 3 months.

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Subjects with evidence of persistent thrombus at 6 weeks time will remain on anticoagulant therapy for 3-6 months at the discretion of their treating physician.

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Subjects with evidence of persistent antiphospholipid antibody at 6 weeks will remain on anticoagulant therapy for 3 months to indefinite duration, at the discretion of their treating physician.
Study: NCT04333381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational and organizational intervention
Description: Patients included after a systematic educational and organizational intervention for early diagnosis and care in myocardial infarction, aimed at emergency nurses of a tertiary Hospital capable in primary PCI.~1. The educational intervention will consist:~   Systematized educational intervention on acute myocardial infarction for emergency triage nurses will consist of theoretical and practical training through case presentations and clinical simulation.~2. The organizational intervention will consist:~   * Development and dissemination of an early diagnostic tool for acute myocardial infarction: STEMI infographics. It will be provided to all emergency nurses and emergency triage boxes~  * Update the STEMI hospital protocol and adapt it to the current clinical guidelines of the European Society of Cardiology (ESC)~  * Review organizational strategies and definition of new improvement measures~  * Audit the delays in STEMI~  * Periodic multi-disciplinary update sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Common Practice
Description: Common practice is based on care by emergency nurses who did not receive any systematized education of acute myocardial infarction led by interventional cardiology nurses. On the other hand, emergency management is based on Plan-Do-Study-Act methodology and in the historical sample some organizational improvement strategies did not exist or were beginning to be implemented
Study: NCT00964106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine dosed at 100 mg as probe for CYP1A2 pathway

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Dosed at 4 mg as probe for CYP2C8 pathway

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: Dosed at 40 mg, probe for CYP2C9 pathway

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Dosed at 20 mg, probe for CYP2C19 pathway

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Dosed at 30 mg, probe for CYP2D6 pathway

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Dosed at 3 mg for Part 1, Part 2 cohorts B and C and 1 mg for Part 2 Cohort A, probe drug for CYP3A4/5 pathway

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Dosed at 10 mg, probe drug for OATP1B1 pathway

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Dosed at 400 mg once-daily Day 1 through Day 9, inhibitor of CYP3A4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Dosed at 400 mg x 1 dose on day 1, 200 mg once daily on days 2 through 9, inhibitor of CYP2C9 pathway

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Dosed at 600 mg x 1 dose on Day 1 and Day 8, inhibitor of OATP1B1 pathway

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Dosed at 15 mg, probe drug for CYP2C8 pathway
Study: NCT02103582

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intervention
Description: Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
Study: NCT02425501

Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: Administration by intravitreal injection
Study: NCT01706718

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bread
Study: NCT02285205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of Lobeglitazone
Description: Lobeglitazone 0.5mg/tablet, orally, 1 tablet once daily for 24 weeks
Study: NCT00442546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 150 milligram (mg)/ day (double blind)
Study: NCT00174629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel/DDP